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Abstract
Recurrent venous thrombosis, arterial thrombosis and pregnancy losses are clinical manifestation associated with
 .antiphospholipid antibody aPL that recognizes negatively charged phospholipid antigens. Enzyme-linked immunosorbent
 .assays ELISA are generally used to determine the presence and specificity of aPL. In this paper, a fluorescence
spectroscopy method has been applied, through monitoring the alteration of fluorescence intensity and anisotropy of a
fluorophore that was incorporated in liposomes to explore the changes of molecular structure or configuration elicited by the
binding aPL with phospholipid antigens. The bilayer surface was markedly ordered by aPL binding as indicated by the
surface-sensitive probe NBD-PE. The binding of aPL on the bilayer surface is saturable. The saturation concentration of
 .aPL is 40% wrw, aPLrlipid for cardiolipin membranes. The binding of aPL on cardiolipin took place in the absence of
b 2-GP1. The addition of b 2-GP1 further increased the anisotropy and decreased the intensity of fluorescence. The binding
of aPL is predominantly attributed to electrostatic interaction, but the configuration of the acyl chains of phospholipid also
plays a role. It is found that the thermal history is important for aPL binding. The incubation at 378C is more favorable for
 .aPL binding than ambient temperature. Normal human serine IgG-NHS did not elicit any distinct change of NBD-PE
fluorescence, which indicates it does not interact with the lipid. Published by Elsevier Science B.V.
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1. Introduction
The association of anti-phospholipid antibodies
 .aPL with recurrent thrombosis and pregnancy loss
w xis well recognized 1–3 . Patients with this disorder
are described as having the ‘Antiphospholipid Syn-
w xdrome’ 4–6 . The mechanism by which these au-
toantibodies are induced, and the nature of the associ-
Published by Elsevier Science B.V.
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ation of anti-phospholipid antibodies with thrombosis
is unknown. There are several clues that these anti-
bodies may play an integral role in the thrombotic
w xprocess 7–15 . A central feature of antiphospholipid
antibodies is that they influence coagulation reactions
catalyzed by phospholipid. The so-called lupus anti-
coagulant reaction is due to the fact that these anti-
bodies inhibit prothrombin to thrombin conversion
w x6,16 . This is a reaction catalyzed by phospholipid,
and it has been demonstrated by several investigators
that an increase of phospholipid in this system will
w xinhibit the reaction 16–19 .
Several investigators present evidence that antibod-
ies with lupus anticoagulant activity may be specific
 .for b 2-glycoprotein 1 b 2-GP1 , a b 2-GP1–phos-
w x w xpholipid complex 20,21 , prothrombin 22 , or a
w xhuman prothrombin–phospholipid complex 23 . The
conformation rather than the type of phospholipid
w xmay determine its antigenicity 24–26 .
It is reasonable to suggest that the conformation
adopted by coagulation proteins in the presence of
phospholipid, and the conformation of phospholipid
in the presence of coagulation proteins may be impor-
tant in determining antibody binding and their resul-
tant functional effects. It is also conceivable that by
binding phospholipid with antibody, these antibodies
andror antigens may impose structural changes,
which may enable circulating phospholipid to serve
as templates for the coagulation reaction. In an effort
to elucidate the structural interactions involved with
the coagulation reactions, as a first step, we have
studied the structure of b 2-GP1, and cardiolipin
w xinteractions using infrared spectroscopy 27 , and
b 2-GP1 interaction with calcium and cardiolipin us-
w xing a head group-labeled fluorescent probe 28 . This
methodology was developed in our laboratory to
w xquantify lens protein–lipid binding 29 . In this study,
b 2-GP1, antiphospholipid antibody, lipid bilayer in-
teractions were assessed using the fluorescent probe
NBD-PE.
2. Materials and methods
2.1. Materials
b 2-GP1 was purchased from Celsius Laboratories,
 .Cincinnati, OH . IgG was isolated from serum of a
 .patient with the antiphospholipid syndrome aPL
using affinity purification with cardiolipin liposomes
and subsequent isolation of IgG with protein G
w xSepharose as described elsewhere 24,30,31 . Purity
was determined by SDS-PAGE single band at 150
.kDa and absence of contamination with b 2GP1 was
determined by immunoblot using a rabbit anti-human
b 2GP1 antiserum. Protein concentration was deter-
w xmined by the Lowry method 32 . Normal human IgG
was obtained from a pool of normal health control
 .sera ns10 by protein G Sepharose chromatogra-
phy.
 .N- 7-nitrobenz-2-oxa-1,3-diazol-4-yl -1,2-di-
hexadecanoyl-sn-glycero-3-phosphoethanolamine tri-
 .ethylammonium salt NBD-PE and diphenylhexa-
 .triene DPH were purchased from Molecular Probes
 .Eugene, OR . The concentration was determined
using an extinction coefficient of 20,000 My1 cmy1
at 460 nm and 91,000 My1 cmy1 at 350 nm in
chloroform, respectively.
 .Phosphate-buffered saline PBS , alkaline-phos-
 .phatase-labeled antihuman immunoglobulin IgG ,
 .p-nitrophenylphosphate, adult bovine serum ABS ,
 .cardiolipin CL , dimyristoylphosphatidylcholine
 .  .DMPC , dipalmitoylphosphatidylcholine DPPC and
1-palm itoy-2-oleoyl-3-sn-phosphatidylcholine
 .  .POPC were purchased from Sigma St. Louis, MO .
The concentration was determined as inorganic phos-
w xphate by the method used by Bartlett 33 or as
specified by the manufacture.
2.2. Liposome preparation
Model membranes composed of phospholipid were
used. Phospholipid and either of the fluorescence
probes NBD-PE or DPH dissolved in chloroform
were mixed together at a weight ratio of fluorescence
probes to phospholipid of 1:200. The solution was
dried under nitrogen, then lyophilized for 4 h to
remove all chloroform. The mixture was suspended
in buffer containing 0.01 M phosphate buffer, 0.0027
M potassium chloride, and 0.137 M sodium chloride,
pH 7.5 at 258C. After suspending the sample using a
 .vortex mixer Fisher Scientific , the lipid probe mix-
ture was sonicated for 5 min at 408C to form vesicles.
After incubation at room temperature for 1 h, the
suspension was divided equally into plastic cuvettes
with antiphospholipid antibody or antiphospholipid
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.antibody and b 2-GP1 added. After mixing with a
vortex mixer, the samples were incubated for 17 h at
room temperature or 378C. Binding was assessed
using an ELISA assay and by fluorescence intensity
and anisotropy measurements described below.
2.3. ELISA
The binding of anticardiolipin and antiphospho-
lipid antibodies was determined by ELISA using
cardiolipin or other phospholipids to coat the plates,
w xas described elsewhere 34,35 . The levels of anticar-
diolipin antibodies were determined in GPL Louis-
.ville APL Diagnostics, Louisville, KY .
2.4. Fluorescence intensity and anisotropy measure-
ment
Fluorescence intensity and anisotropy measure-
ments were made with an ISS PC1 photon counting
 .spectrofluorometer Champaign, IL with polarization
accessory unit. Steady-state fluorescence anisotropy,
r, was measured as
rs I ygI r I q2 gI .  .5 H 5 H
in which gs I rI ; I and I are the perpendicularH 5 H 5
and parallel components of fluorescence observed
corresponding to the plane of polarization of the
excitation beam, respectively. Total fluorescence in-
tensity was calculated as
I s I q2 Itot 5 H
All measurements were made at the equilibrium tem-
perature of 238C or as indicated in the tables and
figure legends. Samples with NBE-PE were excited
at 460 nm, the emission was observed at 540 nm by a
multiphotometer. Samples with DPH were excited at
350 nm, the emission was observed at 452 nm. The
integration time was 5 s. The measuring error was
less than 0.002 for anisotropy. The concentration of
lipid used for fluorescence measurements is 0.26 mM
in the phase transition study and 200 mgrml in the
protein binding study. The total volume of the mix-
ture of lipid and proteins was 1.5 ml. Samples were
stirred by a magnetic bar in the spectrometer cuvette
through the fluorescence measurement.
3. Results
The fluorescent probe, NBD-PE was used to moni-
tor changes in the bilayer surface environment caused
by aPL binding. Addition of aPL to the cardiolipin
membranes induced a dramatic decrease in the fluo-
 .rescence intensity Fig. 1a and a dramatic increase in
 .  .Fig. 1. a Decrease in normalized fluorescence intensity NFI
 .and b increase in fluorescence anisotropy of NBD-PE upon
increasing aPL. The liposomes were prepared from bovine heart
cardiolipin. The measurements were completed at 238C. The
liposomes were bound by aPL at 238C.
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Table 1
Protein–lipid binding parameters measured from fluorescence intensity of NBD-PE probe
Substrate bound to bovine Normalized fluorescence intensity parameters
heart cardiolipin and bovine
DNFI K Cooperativitybw  .heart PC 1:1 wrw , 238C,
xunless indicated
 .  .  .  .aPL binding to cardiolipin no PC y0.58 0.03 18.0 1.3 1.85 0.22
 .  .  .aPL y0.285 0.007 14.7 0.9 2.4 0.3
 .  .  .aPL 378C y0.524 0.044 15.4 2.7 1.1 0.252
 .aPL, 4.0 mg b 2-GP1 y0.626 0.042 -12 N.S.
 .  .  .aPL, 6.3 mg b 2-GP1 y0.689 0.026 1.87 1.31 1.1 0.7
IgG-NHS N.S.) N.S. N.S.
 .IgG-NHS, 3 mg b 2-GP1 y0.105 0.003 -3 N.S.
 .)N.S. not significant .
 .the fluorescence anisotropy Fig. 1b . Note the plateau
in the fluorescence anisotropy and intensity, which
indicates saturable binding occurs above a aPL to
 .cardiolipin ratio of 40% wrw . Using Sigma Plot,
 .version 2 Jandel, San Rafael, CA , nonlinear regres-
sion analysis was used to fit the data in Fig. 1a,b to
 .Eq. 1 below, that was derived from an equation
used to quantify Michaelis–Menten kinetics for en-
w xzymes and lipid structural analysis 36 .
CEquation: Ysminqmaxr 1q K rX 1 .  .b
where Ysanisotropy or fluorescence intensity; Xs
ligandrphospholipid ratio as wt.%; minsminimum
anisotropy or fluorescence intensity; maxsmaximum
change in anisotropy or fluorescence; K swt.%b
ratio for 50% binding, K ; Cscooperativity of bind-b
ing similar to 1rHill coefficient, described by
Michaelis–Menton kinetics. The broader the binding
curve, the lower the cooperativity. Parameters for
Fig. 1a,b are given in Tables 1 and 2, respectively.
Using the fluorescent probe to quantify binding, a K b
 .of 18% wrw and a cooperativity of 1.8 was esti-
mated.
To confirm the binding data determined by fluo-
rescence, an ELISA assay was used to measure the
binding of aPL with bovine heart cardiolipin antigen.
Fig. 2 shows that O.D. at 410 nm increases upon the
incorporation of aPL from 0 to 50% wrw,
.aPLrcardiolipin , and a maximum saturation of aPL
 .is found around 40% wrw, aPLrcardiolipin and a
K of 11.7 and cooperativity of 1.2 was determinedb
 .Table 3 . The binding data from the ELISA and
fluorescence assays were identical not statistically
.different, ps0.030 .
The effect of aPL binding on membranes com-
 .posed of 50% wrw bovine heart cardiolipin and
 .50% wrw bovine heart PC also was studied by
monitoring the change of NBD-PE fluorescence. All
Table 2
Protein–lipid binding parameters measured from anisotropy change of NBD-PE probe
Substrate bound to bovine Anisotropy parameters
heart cardiolipin and bovine
D R K Cooperativity R Rb min maxw  .heart PC 1:1 wrw , 238C,
xunless indicated
 .  .  .  .  .aPL binding to cardiolipin no PC 0.0102 0.0010 24 2.0 4.0 1.3 0.063 0.0006 0.073
 .  .  .  .aPL 0.0106 0.0012 21 2.8 3.2 1.2 0.0709 0.0009 0.082
 .  .  .  .aPL, 378C 0.032 0.003 23 3.5 1.50 0.28 0.086 0.001 0.118
 .  .  .  .aPL, 4.0 mg b 2-GP1 0.039 0.004 19.2 3.3 1.6 0.4 0.086 0.0002 0.125
 .  .  .  .aPL, 6.3 mg b 2-GP1 0.0432 0.0060 12 2.7 1.9 0.7 0.0726 0.0043 0.115
 .  .  .IgG-NHS 0.0094 0.0075 N.S.) 1.26 1.27 0.0972 0.0016 0.107
 .  .  .  .IgG-NHS, 3 mg b 2-GP1 0.020 0.002 5.6 1.2 1.07 0.38 0.093 0.001 0.073
 .)N.S. Not significant .
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Fig. 2. The binding plot of cardiolipin liposome upon the amount
of aPL detected by ELISA at 238C.
of binding parameters from fluorescence intensity
and fluorescence anisotropy are listed in Tables 1 and
2, respectively. From the fluorescence intensity, the
 .K was calculated to be 18.0 without PC and 14.7b
with 50 wt.% PC; from the fluorescence anisotropy,
it was 24.0 without PC and 21.0 with 50 wt.% PC,
respectively. This indicates that aPL binds with the
 .same sensitivity with or without 50% wrw PC.
The DNFI with 50% PC was statistically twofold
 .lower ps0.0001 compared with the DNFI for
cardiolipin alone. This indicates that the capacity to
bind aPL is twofold lower in cardiolipin vesicle with
50% PC. Following the above experiment, an addi-
tional 6.3 mg b 2-GP1 was added into each sample
and incubated at room temperature overnight. b 2-
GP1 caused no significant change in the fluorescence
intensity in the absence of aPL, but caused a signifi-
 .cant ps0.0001 twofold increase in the binding
 .capacity DNFI of aPL to cardiolipinrPC vesicles
 . Table 1 . The K was also significantly lower psb
.0.0001 with 6 mg b 2-GP1 present.
The aPL binding was also tested with the zwitteri-
onic phospholipid DMPC and DPPC as the lipid
matrix. DPPC has a higher phase transition tempera-
 .ture 438C, gelrliquid crystalline phase than DMPC
 .258C, gelrliquid crystalline phase . Binding of aPL
was quantified at 238C and 488C for comparison with
 .cardiolipin Table 4 . In comparison with cardiolipin,
 .the DNFI value binding capacity was 10 times
 .lower for DPPC alone Table 4 , which indicates that
very little, if any, aPL binds to DPPC. The DNFI
value was two times larger when DPPC is in the
liquid–crystalline phase, but the binding capacity was
still five times lower than for cardiolipin alone Table
.4 . Since aPL binds only slightly to DPPC and DMPC
in any phase, the 50% decrease in the binding
capacity of aPL to cardiolipin when PC is present
is elucidated, and suggests that aPL binds only to
cardiolipin when PC is present. After normalization,
the data that were obtained at different temperatures,
before and after the addition of b 2-GP1, was identi-
 .cal Table 4 . From the data above, we conclude that
neither DPPC nor DMPC bound significantly with
aPL or b 2-GP1.
Using our fluorescence probe technique, the bind-
ing activity of aPL that tested positive in the ELISA
assay was compared to an IgG from normal human
 .sera IgG-NHS . IgG-NHS was incorporated into li-
posomes composed of cardiolipin and bovine heart
 .  .PC 1:1, w:w Table 1 . IgG-NHS caused an in-
significant change in the anisotropy and fluorescence
intensity of the NBD-PE probe; thus, no significant
IgG-NHS binding was observed. The addition of 3.0
mg b 2-GP1 in each sample induced a discernible
 .increase in the binding capacity DNFI of aPL;
however, the changes in the binding capacity, DNFI,
for b 2-GP1rIgG-NHS was 6 times smaller than for
aPL. This suggests that even with b 2-GP1, IgG-NHS
binds only slightly to cardiolipinrPC vesicles.
The thermal history of samples influenced
the binding of aPL to the membranes composed of
Table 3
aPL-cardiolipin binding parameters measured from ELISA assay
ELISA assay parameters
DO.D. K Cooperativity O.D.max b min
 .  .  .  .aPL binding to: bovine heart cardiolipin, 238C 0.247 0.049 11.7 1.2 1.2 0.5 0.060 0.011
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Table 4
aPL binding to DPPC measured from changes in NBD-PE fluorescence probe characteristics
Conditions Normalized fluorescence intensity parameters
DNFI K Cooperativityb
 .238C y0.053 0.035 -12 N.S.)
 .488C y0.13 0.22 -12 N.S.
2.5 mg -12 N.S.
b 2-GP1, 488C N.S.
Anisotropy parameters
D R K Cooperativity Rb min
 .238C N.S. N.S. N.S. 0.118 0.005
 .488C N.S. N.S. N.S. 0.060 0.002
 .  .2.5 mg b 2-GP1, 488C 0.017 0.037 N.S. N.S. 0.063 0.002
 .)N.S. not significant .
 .cardiolipin and bovine heart PC 1:1. wrw . As seen
in Table 1, when aPL cardiolipinrPC binding at
238C is compared with the binding at 378C, the
binding capacity, DNFI, was significantly two times
 .higher p-0.0001 at 378C. There is no significant
difference between the K .b
DPH probe was utilized to explore the influence of
aPL binding on the flexibility of acyl chains in
membranes with cardiolipin. The DPH fluorescence
probe has been extensively adopted to study the
anisotropy or polarization of the interior of mem-
Fig. 3. The comparison of binding of aPL to membranes that are
composed of homogeneous liposomes. The ratio of aPL to phos-
 .pholipid is 65% wrw . The unit of Y axis is the relative
w xincrease of anisotropy, r, defined as follows: r y r r r ,with free free
in which r sanisotropy of NBD-PE where aPL present,with
r sanisotropy of NBD-PE where aPL is absent. Spectroscopyfree
measurements and binding equilibration were done at 238C.
branes. We measured samples that were incubated at
ambient temperature and 378C, respectively. aPL
binding caused no obvious change in anisotropy of
DPH suggesting that binding has no effect on the
hydrocarbon chains of the membranes.
To determine if the configuration or the unsatura-
.tion of the acyl chains of phospholipid influence the
binding of aPL, aPL was bound to liposomes pre-
pared from DOPC, bovine heart PC, DMPC and
DPPC. Judging from the relative increase in the
anisotropy of the NBD-PE probe upon aPL binding,
aPL binds in following order: DPPC-POPCs
 .bovine heart PC<CL Fig. 3 .
To test if oxidating conditions influenced the bind-
ing of aPL to cardiolipin, argon purging was omitted
from all protocols. The results obtained without argon
were identical to these obtained with argon.
4. Discussion
The disorder of recurrent venous thrombosis, arte-
 .rial thrombosis strokes, myocardial infarction and
pregnancy loss was recognized in young women with
 .systemic lupus erythematosus SLE . The abnormal-
ity accompanying this disorder is a production of
antiphospholipid antibodies. The disorder is called
the ‘Antiphospholipid Syndrome’; however, the
mechanism of action of antiphospholipid antibody in
this syndromes is unknown. In a first attempt to
elucidate the interactions involved with coagulation,
the binding of aPL to a few select lipid systems and
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the effect of b 2-GP1 on this binding was determined
and compared to the binding of IgG from healthy
humans. It is necessary to systematically study the
condition of aPL binding appearance and the influ-
ence of aPL binding on the structure of antigens and
membranes with antigens.
In the past, the interactions of phospholipid and
antiphospholipid antibody has been determined by an
ELISA assay. Although the ELISA assay is very
sensitive for the binding, it does not reveal molecular
configuration or structure change during the binding
process. In this paper, fluorescence spectroscopy was
used to confirm the binding of phospholipid with
antiphospholipid antibody. The fluorescence method
overcomes the disadvantage of the loss of lipid dur-
ing washing in ELISA, directly giving information
about interaction between liposome and aPL. Fluores-
cence probes can be located in different positions of
lipid membrane and information, such as the change
of molecular configuration during the binding, can be
obtained by monitoring changes of fluorescence in-
tensity and anisotropy upon the addition of aPL.
In our experiments, two different fluorescent
probes were used. NBD-PE was used to monitor the
influence of aPL binding on the head group of phos-
pholipid antigens in membranes, because the fluores-
cent moieties of NBD-PE are situated in the head
group region of the phospholipid bilayer and are thus
sensitive to the change of the surface environment of
w xmembranes 29 . DPH was used to study the effect of
aPL binding on the hydrocarbon chains of phospho-
lipid, because DPH is distributed in the hydrophobic
region of membranes and is sensitive to change in
lipid order at various depths in the hydrophobic
w xbilayer interior 37 . We found that binding did not
influence the anisotropy or fluorescence intensity of
the DPH probe, indicating that the hydrophobic inte-
rior of the bilayers is not affected by aPL binding,
and that large packing changes between vesicles did
not occur.
Cardiolipin was the first antigen found that binds
w xwith aPL 1 . In this paper, the binding of aPL with
cardiolipin was confirmed by NBD-PE fluorescence
spectroscopy.
The increase of probe fluorescence anisotropy and
the decrease of probe fluorescence intensity is at-
tributed to the binding of aPL to cardiolipin. The
increase of NBD-PE fluorescence anisotropy reflects
a decrease of flexibility in the head group region of
the lipid bilayer in the vicinity of aPL. We have
found that the binding of aPL to cardiolipin is sat-
urable with a K of 18 mg aPLr100 mg cardiolipin.b
The incorporation of PC 50% by weight caused a
 .50% decrease in the binding capacity DNFI of aPL
 .Table 1 . The K determined by a decrease inb
fluorescence intensity was lower than that determined
by the increase in anisotropy data, because it is likely
that a greater amount of aPL binding was necessary
 .to elicit a change in the mobility wobble anisotropy
of the probe.
There are at least two possibilities that could ex-
plain the quenching of NBD fluorescence by aPL.
One explanation is that the NBD-PE molecules may
phase-separate from the major lipids during the bind-
ing of aPL. Such a phase separation would increase
the local concentration of NBD-PE, and lead to fluo-
rescence self-quenching. This phenomenon was ob-
served when lipids containing 1 mol% NBD-PE are
w xin the gel phase 38 . A second explanation is that the
quenching of NBD-PE fluorescence after aPL bind-
ing may arise from the exposure of NBD fluorophore
 .moiety to water a quencher . The fluorophore moiety
for NBD is hydrophobic and located at the bilayer
surface, as demonstrated by quenching experiments
w x w x39 and spin-labeled lipids 40 . The binding of aPL
in the environment of NBD moieties may make the
head groups of phospholipids more rigid as indicated
by anisotropy results, forcing the NBD towards the
water that leads to a quenching of fluorescence.
The thermal history of the incubation of the sam-
ples is another important factor that influences aPL
binding to phospholipid antigens. When the same
 .samples 50 wt.% cardiolipin and 50 wt.% PC were
incubated at 238C, less apparent binding was ob-
served as evidenced by a small DNFI and DR value
 .Tables 1 and 2 . When same samples were incubated
at 378C for the same period, the DNFI and DR
values for NBD-PE increased twofold Tables 1 and
.2 . This indicates that physiological temperature is
more favorable to the binding of aPL to membranes
containing cardiolipin.
There are several different opinions about the role
w xof b 2-GP1 in aPL binding 41 . The first is
that b 2-GP1 alone is the antigen recognized by
w xanticardiolipin antibodies. Galli et al. 42 , using anti-
bodies affinity purified from two patients with
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Antiphospholipid Syndrome reported direct
antibody binding to b 2-GP1. The second is that
anticardiolipin antibodies bind a cardiolipin–b 2-GP1
w xcomplex. McNeil et al. 43 found no direct binding
of affinity-purified anticardiolipin antibodies to b 2-
GP1 by column chromatograph, but they reported
that b 2-GP1 was an absolute requirement for bind-
ing to cardiolipin. They proposed that these antibod-
ies bind epitopes shared by cardiolipin and b 2-GP1.
The third opinion is that the b 2-GP1 enhances bind-
w xing to cardiolipin of some patients’ sera 41,44,45 . In
our experiments, an obvious increase of fluorescence
anisotropy and a marked decrease of fluorescence
intensity were found after addition of b 2-GP1 into
 .aPLr cardiolipinqbovine heart PC comparing with
 .aPLr cardiolipinqbovine heart PC alone; however,
we also found a similar increase of anisotropy and a
similar decrease of NBD-PE fluorescence intensity
when b 2-GP1 was incorporated into cardio-
lipinrbovine heart PC mixture. The binding of b 2-
GP1 on acid phospholipid depends predominantly on
the electrostatic interaction of the acidic head group
of phospholipid, and the positively charged amino
w xacid histidine 46,47 . Based on our results, b 2-GP1
enhances the binding of aPL, which must occur via a
conformational change. Although we show that b 2-
GP1 can bind to CL alone, the change in probe DNFI
and xxanisotropy are much greater when aPL and
b 2-GP1 are together than when the system is satu-
rated with aPL or b 2-GP1 alone. Our results elimi-
w xnate the possibility proposed by Galli et al. 42 that
b 2-GP1 alone is the antigen for aPL, since aPL alone
can bind with phospholipid at appropriate incubation
condition even in the absence b 2-GP1.
Through the comparison of binding data using
DMPC, DPPC, POPC, bovine heart PC and
cardiolipin as antigen with aPL present and aPL
absent, we have found that the anisotropy of NBD-PE
was raised by the incorporation of aPL to a different
 .extent Fig. 3 . The relative change in anisotropy
follows the order: cardiolipin4bovine heart PC)
POPC)DMPC)DPPC. The negatively charged
head group of cardiolipin greatly enhances binding
compared with all forms of phosphatidylcholine Fig.
.3 . DPPC is completely ordered at 238C and binds
 .aPL less than DMPC Fig. 3 . Thus, hydrocarbon
chain order and aPL binding are correlated. It is
possible that the ability of bound aPL to raise the
anisotropy of NBD-PE in DPPC is less than DMPC,
since DPPC is more ordered, and the anisotropy is
already as high as possible. The influence of the acyl
chains on aPL binding was explored by Levy et al.
w x48 using the ELISA method. They found the poten-
tial role of the fatty acid chains on a PL binding by
monitoring the effect of degradation of phos-
phatidylethanolamine by loss of an acyl chain group
w xto lyso phosphatidylethanolamine 49 .
IgG-NHS does not change the fluorescence inten-
sity and anisotropy of NBD-PE in CLrPC, PC and
DMPC liposome. This is a hint that ‘Antiphospholi-
pid Syndrome’ is attributed to the binding of aPL to
lipid membranes. Weak binding of IgG-NHS is ob-
served when b 2-GP1 is added, but even with b 2-
GP1, the extent of IgG-NHS binding is much less
than for aPL.
Acknowledgements
This work is supported by a grant from the Jewish
Hospital, Louisville KY and USPHS grant EY07975
and an unrestricted grant from Research to Prevent
Blindness.
References
w x1 E.N. Harris, Antiphospholipid antibodies and cardiovascular
 .disease, in: R.B. Francis Ed. , Atherosclerotic Cardiovascu-
lar Disease, Hemostasis, and Endothelial Function, Marcel
Dekker, New York, 1992, pp. 237–276.
w x2 D.A. Triplett, J.T. Brandt, Lupus anticoagulants: misnomer,
 .paradox, riddle, epiphenomena, Hematol. Pathol. 2 1988
121–143.
w x3 P.E. Love, S.A. Santoro, Antiphospholipid antibodies: anti-
cardiolipin and lupus anticoagulant in systemic lupus erythe-
 .matosus SLE and in non-SLE disorders: prevalence and
 .clinical significance, Ann. Intern. Med. 12 1990 682–698.
w x4 E.N. Harris, Syndrome of the Black Swan, Br. J. Rheuma-
 .tol. 26 1987 324–326.
w x5 R.A. Asherson, A ‘primary’ antiphospholipid syndrome?, J.
 .Rheumatol. 15 1988 1742–1746.
w x6 D. Alarcon-Segovia, J. Sanchez-Guerrero, J. Rheumatol. 16
 .1989 482–488.
w x7 E.N. Harris, J.K.H. Chan, R.A. Asherson, V.R. Aber, A.E.
Ghavari, G.R.V. Hughes, Thrombosis, recurrent fetal loss,
thrombocytopenia; predictive value of IgG anticardiolipin
 .antibodies, Arch. Intern. Med. 88 1990 112–116.
w x8 M.D. Lockshin, M.L. Druzin, T. Qatar, Prednisone does not
( )D. Tang et al.rBiochimica et Biophysica Acta 1372 1998 45–54 53
prevent recurrent fetal death in women with antiphospho-
 .lipid antibodies, Am. J. Obstet. Gynecol. 160 1989 439–
443.
w x9 B.M. Alving, C.F. Barr, D.D. Tang, Correlation between
lupus anticoagulants and anti cardiolipin antibodies in pa-
tients with prolonged activated partial thromboplastin times,
 .Am. J. Med. 88 1990 112–116.
w x10 S. Loizou, M.A. Byron, H.R. Englert, M.J. Walport, G.R.V.
Hughes, Association of quantitative anti-cardiolipin anti-
 .body levels with fetal loss, Q. J. Med. 68 1998 525–531.
w x11 D.W. Branch, D.J. Dudley, M.D. Mitchell, K.A. Creightari,
J.M. Abbott, E.H. Hammond, R.A. Daynes, Immunoglobu-
lins G fractions from patients with antiphospholipid antibod-
ies causes fetal death in Balbrc mice: a model for autoim-
 .mune fetal loss, Am. J. Obstet. Gynecol. 163 1990 210–
216.
w x12 M. Blank, J. Cohen, V. Toder, Y. Shoenfeld, Proc. Natl.
 .Acad. Sci. U.S.A. 88 1993 3069–3073.
w x13 R. Bakimer, P. Fishman, M. Blank, B. Srednc, M. Djaidetti,
Y. Shoenfeld, Induction of primary antiphospholipid syn-
drome in mice by immunization with a human monoclonal
 .  .anticardiolipin antibody H-3 , J. Clin. Invest. 89 1992
1558–1563.
w x14 H.R. Smith, C.L. Hansen, R. Rose, R.T. Canoso, Autoim-
mune MRl-lprrlpr mice are an animal model for the sec-
 .ondary antiphospholipid syndrome, J. Rheumatol. 17 1990
911–915.
w x15 A.E. Gharavi, Anti-phospholipid syndrome in mice, in: E.N.
 .Harris, T. Exner, G.V.R. Hughes, R.A. Asherson Eds. ,
Phospholipid Binding Antibodies, CRC Press, Boca Raton,
FL, 1991, pp. 403–416.
w x16 M. Galli, S. Beguin, T. Lindout, C.H. Hemker, Inhibition of
phospholipid and platelet-dependent prothrombinase activity
in the plasms of patients with lupus anticoagulants, Br. J.
 .Haematol. 72 1989 549–555.
w x17 J.T. Brandt, Assay for phospholipid-dependent formation of
thrombin and factor Xa: a potential method for quantifying
 .lupus anticoagulants, Thromb. Haemost. 66 1991 453–458.
w x18 A.J. Marcus, H.L. Ullman, L.B. Safier, Lipid composition
of subcellular particles of human blood platelets, J. Lipid
 .Res. 10 1969 108–115.
w x19 D.A. Triplett, J.T. Brandt, Lupus anticoagulants: misnomer,
 .paradox, riddle, epiphenomena, Hematol. Pathol. 2 1988
121–143.
w x20 J.D. Oosting, R.H.W.M. Derksen, T.I. Entjes, B.N. Bouma,
P.G. de Groot, Lupus anticoagulant activity is frequently
dependent on the presence of b 2 glycoprotein1, Thromb.
 .Haemostasis 67 1992 499–502.
w x21 M. Galli, P. Comfurius, T. Barbui, R.F.A. Zwaal, E.M.
Bevers, Anticoagulant activity of beta 2-glycoprotein 1 is
potentiated by a distinct subgroup of anticardiolipin antibod-
 .ies, Thromb. Haemostasis 68 1992 297–300.
w x22 R.A. Fleck, S.E. Rapaport, L.V.M. Rao, Anti-prothrombin
 .antibodies and the lupus anticoagulant, Blood 72 1989
512–519.
w x23 E.M. Bevers, M. Galli, T. Barbui, P. Camfurius, R.F.A.
Zwaa, Lupus anticoagulant IgG’s prothrombin, Thromb.
 .Haemostasis 66 1991 629–632.
w x24 E.N. Harris, A.E. Gharavi, A. Tincani, J.K.H. Chan, G.
Balestrieri, G.R.V. Hughes, Affinity-purified anti-cardioli-
pin antibodies and anti-DNA antibodies, J. Clin. Lab. Im-
 .munol. 17 1985 155–162.
w x25 E.N. Harris, A.E. Gharavi, G.D. Wasley, G.R.V. Hughes,
Use of an enzyme-linked immunosorbent assay and of inhi-
bition studies to distinguish between antibodies to cardi-
olipin from patients with syphilis of autoimmune disorders,
 .J. Infect. Dis. 157 1988 23–31.
w x26 J. Rauch, M. Tannenbaum, H. Tannenbaum, H. Ramelion,
P.R. Cullis, C.P.S. Tilcock, M.J. Hope, A.S. Janoff, Human
hybridoma lupus anticoagulants distinguish between bilayer
and non-bilayer phase lipid systems, J. Biol. Chem. 261
 .1986 9672–9677.
w x27 D. Borchamn, E.N. Harris, S.S. Pierangeli, O.P. Lamba,
Interactions and molecular structure of cardiolipin and beta
 .  .2-glycoprotein 1 b 2-GP1 , Clin. Exp. Immunol. 102 1995
373–378.
w x28 D. Borchamn, D. Tang, N. Harris, S. Pierangeli, The struc-
ture of cardiolipin-phosphatidylcholine membranes and the
effect of calcium and beta2-GP1 binding as explored by the
fluorescence probe NBD-PE, submitted.
w x29 D. Borchman, D. Tang, Binding capacity of a-crystalline to
 .bovine lens lipids, Exp. Eye Res. 63 1996 407–410.
w x30 S.S. Pierangeli, E.N. Harris, G.H. Goldsmith, A.E. Gharavi,
D.W. Branch, W.L. Dean, Are immunoglobulins with lupus
anticoagulant activity specific for phospholipids?, Br. J.
 .Haematol. 85 1993 124–132.
w x31 S.S. Pierangeli, G.H. Goldsmith, S. Krnic, E.N. Harris,
Difference in functional activity of anticardiolipin antibodies
from patients with syphilis and the antiphospholipid syn-
 .drome, Infect. Immunol. 62 1994 4081–4084.
w x32 O.H. Lowry, N.J. Rosebrough, A.L. Farr, R.J. Randall,
Protein measurement with the folin phenol reagent, J. Biol.
 .Chem. 193 1951 265–275.
w x33 G.R. Bartlett, Phosphorus assay in column chromatography,
 .J. Biol. Chem. 234 1959 466–468.
w x34 E.N. Harris, Annotation: antiphospholipid antibodies, Br. J.
 .Haematol. 74 1990 1–9.
w x35 E.N. Harris, S.S. Pierangeli, D. Birch, Anticardiolipin wet
workshop report: Vth International Symposium on An-
 .tiphospholipid Antibodies, Am. J. Clin. Pathol. 101 5
 .1994 616–624.
w x36 D. Borchman, Y. Oriki, O.P. Lamba, W.C. Byrdwell, M.C.
Yappert, Age and regional structural characterization of
lipid hydrocarbon chains from human lenses by infrared,
and near-infrared Raman, spectroscopies, Biospectroscopy 2
 .1996 113–123.
w x37 B.R. Lentz, D.A. Barro, M. Hoechli, Cholesterol–phos-
phatidycholine interactions in multilamellar vesicles, Bio-
 .chemistry 19 1980 1943–1954.
w x38 J. Wylie, R.E. Pagano, Kinetics of soluble lipid monomer
 .diffusion between vesicles, Biochemistry 20 1981 2783–
2789.
( )D. Tang et al.rBiochimica et Biophysica Acta 1372 1998 45–5454
w x39 K. Hong, P.A. Baldwin, T.M. Allen, D. Papahadjopoulos,
Fluorometric detection of the bilayer-to-hexagonal phase
 .transition in liposomes, Biochemistry 27 1988 3947–3955.
w x40 A. Chattopadhyay, E. London, Spectropic and ionization
 .properties of N- 1-nitronenz-2-oxa-1,3-diazol-4-yl -labeled
lipids in model membranes, Biochim. Biophys. Acta 938
 .1988 24–34.
w x41 S. Pierangeli, G. Goldsmith, E.N. Harris, A.E. Gharavi,
 .D.W. Branch, W.I. Dean, Arthritics Rheum. 35 1992 S69,
Abstract.
w x42 M. Galli, P. Comfurius, C. Maasen, H.C. Hemker, M.H.
Debiets, P.J.C. Van Bred-Vriesman, T. Barbui, R.F.A.
Zwaal, E.M. Bevers, Anticardiolipin antibodies directed not
to cardiolipin but to a plasma protein cofactor, Lancet 335
 .1990 1544–1547.
w x43 H.P. McNeil, R.J. Simpson, C.N. Chesterman, S. Krilis,
Anti-phospholipid antibodies are directed against a complex
antigen that includes a lipid-binding inhibitor of coagula-
tion: b 2 glycoprotein 1, Proc. Natl. Acad. Sci. U.S.A. 87
 .1990 4120–4124.
w x44 E. Matsuura, Y. Igarashi, M. Fujimoto, K. Ichikawa, T.
Koike, Anticardiolipin cofactors and differential diagnosis
 .of autoimmune disease, Lancet 336 1990 177–178.
w x45 L.R. Sammaritano, M.D. Lockshin, A.E. Gharavi, Antiphos-
pholipid antibodies differ in aPL cofactor requirement, Lu-
 .pus 1 1992 83–90.
w x46 S.A. Lauer, U. Hempel, A. Gries, K.H. Frank, Amino acid
 .sequence of the region of beta 2-glycoprotein 1 gp1 which
mediates binding of autoantibodies to the cardiolipin–gp1
 .complex in humans, Immunology 80 1993 22–28.
w x47 J. Hunt, S. Krilis, The fifth domain of b 2-glycoprotein 1
 .contains a phospholipid binding site cys281-cys288 and a
region recognized by anticardiolipin antibodies, J. Immunol.
 .152 1994 653–659.
w x48 R.A. Levy, A.E. Gharavi, L.R. Sammaritano, L.V. Habina,
M.D. Lockshin, Fatty acid chain is a critical epitope for
 .antiphospholipid antibody, J. Clin. Immunol. 10 1990
141–145.
w x49 T. Qamar, A.E. Gharavi, R.A. Levy, M.D. Lockshin,
Lysophosphatidylethanolamine is the antigen to which ap-
parent antibody to phosphatidylethanolamine binds, J. Clin.
 .Immunol. 10 1990 260–263.
